SEC Form 4 · accession 0001213900-17-002501
Actinium Pharmaceuticals, Inc. · ATNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kaushik J Dave
Officer — CEO and Interim CFO · Director
Period of report
Mar 14, 2017
Accepted (ET)
Mar 16, 2017 · 6:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388320
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $1.39 | Mar 14, 2017 | A | 250,000 | A | — | Mar 14, 2027 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones.